Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.44 +2.5%	$2.50	$1.28 ▼ $7.85	$267.70M	1.3	1.12 million shs	2.66 million shs
FDMT 4D Molecular Therapeutics	$7.26 +2.3%	$4.68	$2.23 ▼ $17.41	$339.06M	2.83	2.42 million shs	1.11 million shs
GLUE Monte Rosa Therapeutics	$4.58 +5.3%	$4.97	$3.50 ▼ $12.40	$282.86M	1.42	436,530 shs	535,084 shs
STRO Sutro Biopharma	$0.88 +12.5%	$0.80	$0.52 ▼ $5.17	$74.43M	1.66	448,691 shs	1.31 million shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	+2.52%	+3.39%	+1.67%	+21.39%	-56.51%
FDMT 4D Molecular Therapeutics	+2.25%	+28.95%	+70.42%	+111.05%	-49.69%
GLUE Monte Rosa Therapeutics	+5.29%	+4.57%	-18.36%	+15.08%	+1.78%
STRO Sutro Biopharma	+12.55%	+9.42%	+16.01%	-3.69%	-75.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	3.1785 of 5 stars	3.5	3.0	0.0	3.2	2.5	0.6
FDMT 4D Molecular Therapeutics	2.2599 of 5 stars	3.3	2.0	0.0	2.2	1.7	0.6
GLUE Monte Rosa Therapeutics	2.8357 of 5 stars	3.3	1.0	0.0	2.7	1.7	1.9
STRO Sutro Biopharma	4.2778 of 5 stars	3.1	5.0	4.7	2.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	3.00	Buy	$12.50	412.30% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	318.73% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	234.79% Upside
STRO Sutro Biopharma	2.14	Hold	$4.47	408.73% Upside

Current Analyst Ratings Breakdown

Latest STRO, ANNX, GLUE, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/14/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/12/2025	STRO Sutro Biopharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$4.00 ➝ $3.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/16/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$2.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$2.75 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	8,476.05	N/A	N/A	$9.01 per share	0.81
GLUE Monte Rosa Therapeutics	$75.62M	3.74	N/A	N/A	$4.34 per share	1.06
STRO Sutro Biopharma	$62.04M	1.20	N/A	N/A	($0.38) per share	-2.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.18	0.00	N/A	N/A	N/A	-64.57%	-54.35%	N/A
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.53	0.00	N/A	N/A	-594,375.81%	-40.15%	-36.43%	N/A
GLUE Monte Rosa Therapeutics	-$72.70M	$0.36	12.72	N/A	N/A	13.58%	9.95%	6.42%	N/A
STRO Sutro Biopharma	-$227.46M	-$2.53	0.00	N/A	N/A	-201.32%	-852.70%	-58.67%	N/A

Latest STRO, ANNX, GLUE, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million
8/7/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	-$0.15	+$0.16	-$0.15	$7.23 million	$23.19 million
8/7/2025	Q2 2025	STRO Sutro Biopharma	-$0.39	-$0.14	+$0.25	-$0.14	$14.55 million	$63.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	7.99	7.99
FDMT 4D Molecular Therapeutics	N/A	8.75	12.36
GLUE Monte Rosa Therapeutics	N/A	7.16	5.61
STRO Sutro Biopharma	N/A	3.12	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
FDMT 4D Molecular Therapeutics	99.27%
GLUE Monte Rosa Therapeutics	79.96%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
FDMT 4D Molecular Therapeutics	9.60%
GLUE Monte Rosa Therapeutics	6.90%
STRO Sutro Biopharma	3.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.71 million	96.69 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.70 million	42.22 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.76 million	57.50 million	Optionable
STRO Sutro Biopharma	240	84.77 million	81.72 million	Optionable

STRO, ANNX, GLUE, and FDMT Headlines

Recent News About These Companies

Sutro Biopharma (STRO) Gets a Buy from Truist Financial

August 14 at 10:10 AM | theglobeandmail.com

Sutro Biopharma (NASDAQ:STRO) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company

August 14 at 2:55 AM | americanbankingnews.com

Wells Fargo & Company Cuts Sutro Biopharma (NASDAQ:STRO) Price Target to $3.00

August 13 at 8:49 AM | marketbeat.com

Sutro Biopharma price target lowered to $3 from $4 at Wells Fargo

August 12, 2025 | msn.com

Sutro Biopharma (NASDAQ:STRO) Rating Increased to Hold at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Sutro Biopharma (NASDAQ:STRO) Upgraded at Wall Street Zen

August 10, 2025 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO) and Relay Therapeutics (RLAY)

August 9, 2025 | theglobeandmail.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 8, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $6.11 Consensus PT from Brokerages

August 8, 2025 | americanbankingnews.com

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

August 7, 2025 | globenewswire.com

Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts

August 5, 2025 | marketbeat.com

Sutro Biopharma (NASDAQ:STRO) Trading 0.6% Higher - Time to Buy?

August 3, 2025 | marketbeat.com

Sutro Biopharma, Inc.: Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 24, 2025 | finanznachrichten.de

Here's Why Sutro Biopharma (NASDAQ:STRO) Must Use Its Cash Wisely

July 23, 2025 | finance.yahoo.com

Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 23, 2025 | finance.yahoo.com

Sutro Biopharma upgraded to Overweight from Neutral at Piper Sandler

June 16, 2025 | msn.com

Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

June 2, 2025 | finance.yahoo.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

May 9, 2025 | finanznachrichten.de

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

STRO, ANNX, GLUE, and FDMT Company Descriptions

Annexon NASDAQ:ANNX

$2.44 +0.06 (+2.52%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.44 +0.00 (+0.20%)

As of 08/15/2025 07:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

4D Molecular Therapeutics NASDAQ:FDMT

$7.26 +0.16 (+2.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$7.20 -0.05 (-0.76%)

As of 08/15/2025 07:59 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.58 +0.23 (+5.29%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$4.58 +0.00 (+0.11%)

As of 08/15/2025 07:04 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Sutro Biopharma NASDAQ:STRO

$0.88 +0.10 (+12.55%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.89 +0.01 (+1.37%)

As of 08/15/2025 07:43 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time